Clinical trial
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And…
NCT00147550 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00147550 |
|---|---|
| Title | MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma. |
| Official title | A Multicenter, Open-Label, Noncomparative Phase 1-2 Clinical And Pharmacokinetic Study Of Oral PD 0325901 In Patients With Advanced Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma, Colonic Neoplasms, Breast Neoplasms |
| Intervention type | Drug |
| Interventions | PD-0325901 |
| Enrollment | 79 |
| Start date | Feb 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | Jul 1, 2013 |
| First posted | Sep 7, 2005 |
| Last update posted | Sep 13, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: